

## DESCRIPTION



<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human CEACAM-6/CD66c in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human CEACAM-1, -3, or -5 is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>2A</sub> Clone # 439424
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human CEACAM-6/CD66c Lys35-Gly320 Accession # P40199
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 µg/mL	Recombinant Human CEACAM-6/CD66c (Catalog # 3934-CM)
<b>Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM-6), previously called nonspecific cross-reacting antigen (NCA) or CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily (1-4). In humans, CEACAMs include type I transmembrane proteins (CEACAM-1, -3, and -4) and Glycosylphosphatidylinositol (GPI)-linked molecules (CEACAM-5 through -8) (1). There is no human CEACAM-2. Human CEACAM-6 is a 90 kDa, GPI-linked membrane protein that contains a 34 amino acid (aa) signal sequence, a 286 aa extracellular domain (ECD), and a 24 aa hydrophobic C-terminal propeptide. The GPI membrane anchor is attached at the C-terminus following cleavage of the propeptide. CEACAM-6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains (2-4). It shows considerable glycosylation, including (sialyl) Lewis<sup>x</sup>, which mediates binding to E-Selectin, Galectins and some bacterial fimbriae (1, 2). Mature human CEACAM-6 shows 84%, 85%, 80%, 87% and 51% aa identity to the equivalent extracellular regions of human CEACAMs -1, -5 (CEA) and -8, rhesus CEACAM-2, and bovine CEACAM-6, respectively. CEACAM-6 is expressed by granulocytes and their precursors. Activation enhances surface expression by mobilizing CEACAM-6 from storage in azurophilic granules (5, 6). It often shows aberrant expression in acute lymphocytic leukemias (10). CEACAM-6 is also expressed in epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas and hyperplastic polyps (7, 8). Over-expression confers resistance to adhesion-related apoptosis (anoikis) in tumor cells (8, 9). CEACAM-6 is an intercellular adhesion molecule, forming both homotypic, and heterotypic bonds with CEACAM-1, -5 and -8 through interaction of the V-type Ig-like domains (11, 12). Cross-linking of neutrophil CEACAM-6 augments Integrin  $\alpha_3\beta_3$  and  $\beta_2$ -mediated adhesion, apparently by Src and Caveolin-mediated inside-out Integrin activation (8, 13, 14).

## References:

1. Beauchemin, N. *et al.* (1999) *Exp. Cell Res.* **252**:243.
2. Skubitz, K.M. *et al.* (1999) *J. Biol. Regul. Homeost. Agents* **13**:244.
3. Barnett, T. *et al.* (1988) *Genomics* **3**:59.
4. Tawaragi, Y. *et al.* (1988) *Biochem. Biophys. Res. Comm.* **150**:89.
5. Kuroki, M. *et al.* (1995) *Immunol. Invest.* **24**:829.
6. Ducker, T.P. and K.M. Skubitz (1992) *J. Leukoc. Biol.* **52**:11.
7. Scholzel, S. *et al.* (2000) *Am. J. Pathol.* **156**:595.
8. Duxbury, M.S. *et al.* (2004) *J. Biol. Chem.* **279**:23176.
9. Ilantzis, C. *et al.* (2002) *Neoplasia* **4**:151.
10. Kalina, T. *et al.* (2005) *BMC Cancer* **5**:38.
11. Oikawa, S. *et al.* (1992) *Biochem. Biophys. Res. Commun.* **186**:881.
12. Kuroki, M. *et al.* (2001) *J. Leukoc. Biol.* **70**:543.
13. Duxbury, M.S. *et al.* (2004) *Biochem. Biophys. Res. Comm.* **317**:133.
14. Skubitz, K.M. *et al.* (1999) *J. Leukoc. Biol.* **60**:106.